A recently published case report of four ALK-positive lung cancer patients with RBN revealed that all of the patients had seen a decrease in RBN and that three had experienced symptom improvement after bevacizumab (15 mg/kg every 3–4 weeks) was added to their ALK-TKI therapy (59). Here, ALK is linked to lung cancer.